[Correlation of the clinical and pharmaco-dynamic effects of Niamid in the treatment of severely mentally retarded children].
D006916:5-Hydroxytryptophan; D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004314:Down Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid; D008607:Intellectual Disability / Q000188:drug therapy*; D008297:Male; D008333:Mandelic Acids; D009526:Nialamide / Q000627:therapeutic use*; D014556:Urine; D014977:Xanthurenates
D008333:Mandelic Acids; D014977:Xanthurenates; D006897:Hydroxyindoleacetic Acid; D006916:5-Hydroxytryptophan; D009526:Nialamide
Corrélations cliniques et pharmacodynamiques du Niamid chez les oligophrenes profonds.